Non-alcoholic fatty liver disease (NAFLD) has become one of the most common forms of
chronic liver disease worldwide and its prevalence is expected to continue rising. NAFLD …

The conventional paradigm of nonalcoholic fatty liver disease representing the “hepatic
manifestation of the metabolic syndrome” is outdated. We identified and summarized …

An improved understanding of non-alcoholic fatty liver disease epidemiology would lead to
identification of individuals at high risk of developing chronic liver disease and extra-hepatic …

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases
worldwide, as it affects up to 30% of adults in Western countries. Moreover, NAFLD is also …

As obesity reaches epidemic proportions, nonalcoholic fatty liver disease (NAFLD) is
becoming a frequent cause of patient referral to gastroenterologists. There is a close link …

With nonalcoholic steatohepatitis (NASH), NASH cirrhosis, and NASH-related hepatocellular
carcinoma becoming increasingly prevalent, the need for effective therapies has never been …

Background: Clinical predictors of advanced non-alcoholic liver disease (NAFLD) are
needed to guide diagnostic evaluation and treatment. Methods: To better understand the …

Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2
diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia …

Abstract Background and Aim: Studies have shown monounsaturated oleic acid to be less
toxic than palmitic acid and to prevent/attenuate palmitic acid hepatocites toxicity in steatosis …

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver
diseases worldwide, causing considerable liver-related mortality and morbidity. During the …